These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 19643608

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Benbow JW, Andrews KA, Aubrecht J, Beebe D, Boyer D, Doran S, Homiski M, Hui Y, McPherson K, Parker JC, Treadway J, Vanvolkenberg M, Zembrowski WJ.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2220-3. PubMed ID: 19285862
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):306-14. PubMed ID: 18538760
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Mattei P, Boehringer M, Di Giorgio P, Fischer H, Hennig M, Huwyler J, Koçer B, Kuhn B, Loeffler BM, Macdonald A, Narquizian R, Rauber E, Sebokova E, Sprecher U.
    Bioorg Med Chem Lett; 2010 Feb 01; 20(3):1109-13. PubMed ID: 20031405
    [Abstract] [Full Text] [Related]

  • 7. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
    Tsai TY, Hsu T, Chen CT, Cheng JH, Chiou MC, Huang CH, Tseng YJ, Yeh TK, Huang CY, Yeh KC, Huang YW, Wu SH, Wang MH, Chen X, Chao YS, Jiaang WT.
    Bioorg Med Chem Lett; 2009 Apr 01; 19(7):1908-12. PubMed ID: 19269819
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF.
    Curr Opin Investig Drugs; 2008 Apr 01; 9(4):402-13. PubMed ID: 18393107
    [Abstract] [Full Text] [Related]

  • 10. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
    Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE.
    J Med Chem; 2003 Jun 19; 46(13):2774-89. PubMed ID: 12801240
    [Abstract] [Full Text] [Related]

  • 11. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
    Banno Y, Miyamoto Y, Sasaki M, Oi S, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Tsubotani S, Tani A, Funami M, Tawada M, Yamamoto Y, Aertgeerts K, Yano J, Maezaki H.
    Bioorg Med Chem; 2011 Aug 15; 19(16):4953-70. PubMed ID: 21764322
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
    Wang L, Zhang B, Ji J, Li B, Yan J, Zhang W, Wu Y, Wang X.
    Eur J Med Chem; 2009 Aug 15; 44(8):3318-22. PubMed ID: 19375196
    [Abstract] [Full Text] [Related]

  • 13. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
    Wallace MB, Feng J, Zhang Z, Skene RJ, Shi L, Caster CL, Kassel DB, Xu R, Gwaltney SL.
    Bioorg Med Chem Lett; 2008 Apr 01; 18(7):2362-7. PubMed ID: 18346892
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J, Peng L, Zhang G, Lan X, Li C, Chen F, Zhou Y, Lin Z, Chen L, Dai R, Xu H, Yang L, Zhang X, Hu W.
    Eur J Med Chem; 2011 Jan 01; 46(1):71-6. PubMed ID: 21106276
    [Abstract] [Full Text] [Related]

  • 17. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T, Moritoh Y, Kataoka O, Suzuki N, Takeuchi K, Odaka H.
    Life Sci; 2009 Jul 17; 85(3-4):122-6. PubMed ID: 19427871
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
    Madar DJ, Kopecka H, Pireh D, Yong H, Pei Z, Li X, Wiedeman PE, Djuric SW, Von Geldern TW, Fickes MG, Bhagavatula L, McDermott T, Wittenberger S, Richards SJ, Longenecker KL, Stewart KD, Lubben TH, Ballaron SJ, Stashko MA, Long MA, Wells H, Zinker BA, Mika AK, Beno DW, Kempf-Grote AJ, Polakowski J, Segreti J, Reinhart GA, Fryer RM, Sham HL, Trevillyan JM.
    J Med Chem; 2006 Oct 19; 49(21):6416-20. PubMed ID: 17034148
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.